BioArctic AB (publ) (LON:0RV2)

London flag London · Delayed Price · Currency is GBP · Price in SEK
236.92
-3.13 (-1.30%)
At close: Feb 19, 2025
4.31%
Market Cap 1.61B
Revenue (ttm) 18.57M
Net Income (ttm) -12.78M
Shares Out n/a
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,755
Average Volume 8,212
Open 237.60
Previous Close 240.05
Day's Range 235.20 - 240.00
52-Week Range 9.98 - 20.77
Beta -0.26
RSI 63.58
Earnings Date Feb 13, 2025

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheim... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 107
Stock Exchange London Stock Exchange
Ticker Symbol 0RV2
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.